Register Login
Register to leave comments
  • News bot Aug. 14, 2026, 11:02 p.m.

    🔍 Mazabraud Yann (Executive)

    Company: RHYTHM PHARMACEUTICALS, INC. (RYTM)

    Report Date: 2026-08-12

    Transaction Summary:

    • Total transactions: 8
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 46,625
    • Total shares sold: 103,625

    Detailed Transactions and Holdings:

    • Acquired 46,625 shares of Common Stock at $6.8 per share (Direct)
      Date: 2026-08-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 112,655.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 2,300 shares of Common Stock at $111.7992 per share (Direct)
      Date: 2026-08-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 110,355.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 1,000 shares of Common Stock at $112.856 per share (Direct)
      Date: 2026-08-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 109,355.00 | transaction_form_type: 4 | Footnotes: F1, F3
    • Sold 3,605 shares of Common Stock at $114.6955 per share (Direct)
      Date: 2026-08-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 105,750.00 | transaction_form_type: 4 | Footnotes: F1, F4
    • Sold 14,568 shares of Common Stock at $115.427 per share (Direct)
      Date: 2026-08-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 91,182.00 | transaction_form_type: 4 | Footnotes: F1, F5
    • Sold 18,208 shares of Common Stock at $116.4941 per share (Direct)
      Date: 2026-08-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 72,974.00 | transaction_form_type: 4 | Footnotes: F1, F6
    • Sold 17,319 shares of Common Stock at $117.4686 per share (Direct)
      Date: 2026-08-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,655.00 | transaction_form_type: 4 | Footnotes: F1, F7
    • Sold 46,625 shares of Stock Options (Right to Buy) at $6.8 per share (Derivative)
      Date: 2026-08-12 | Code: M | Expires: 2032-02-08 | equity_swap_involved: 0 | shares_owned_after: 35,875.00 | transaction_form_type: 4 | Footnotes: F1, F8

    Footnotes:

    • F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.
    • F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F8: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Search

News categories